[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intermittent-systematic-chemotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intermittent-systematic-chemotherapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100541590","phase-2-stop-and-go-strategy-as-first-line-treatment-for-widely-metastatic-nasopharyngeal-carcinoma-100541590",false,"NCT06331845","Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma","Stop and go Strategy as First-line Treatment in Patients With Objective Response After Systematic Chemotherapy for Widely de Novo Metastatic Nasopharyngeal Carcinoma: A Phase II Trial","Inclusion Criteria:\n\n1. Patients with multiple metastases at first diagnosis or multiple metastases after treatment(multiple metastases were defined as more than 5 lesions and\u002For more than 2 metastasis organs); Histologically or cytologically confirmed multiple metastatic NPC.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at trial entry, and life expectancy ≥ 6 months as judged by the Investigator;\n3. The disease must be measurable with at least 1 unidimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; Adequate organ function;\n4. Take adequate contraceptive measures throughout the study, and contraception continues until 12 months after treatment;\n5. Able and willing to provide a signed informed consent form, and able to comply with all procedures.\n6. The time from the last chemotherapy and\u002For radiotherapy to randomization must be ≥6 months.\n\nExclusion Criteria:\n\n1. Patients with a hypersensitivity to any of the drugs used in our study;\n2. With any active autoimmune disease or history of autoimmune disease;\n3. Clinically significant cardiovascular and cerebrovascular diseases;\n4. Have or are suffering from other malignant tumors within 5 years (except non-melanoma skin cancer or pre-invasive cervical cancer);\n5. Active systemic infection;\n6. Drug or alcohol abuse;\n7. No or limited capacity for civil conduct;\n8. The patient has a physical or mental disorder, and the researcher considers that the patient is unable to fully or fully understand the possible complications of this study;\n9. History of immunodeficiency including seropositive for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or any active systemic viral infection requiring therapy；\n10. Use cortisol or other systematic immunosuppressive medications within 4 weeks before the study treatment, and the subject requiring hormone therapy during trials.\n11. Pregnancy or breastfeeding.","ALL","18 Years","70 Years",{"count":20,"type":21},39,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic chemotherapy (SC).",[27,28],"Metastatic Nasopharyngeal Carcinoma","Intermittent Systematic Chemotherapy",[30,31,32],"metastatic nasopharyngeal carcinoma","systematic chemotherapy","intermittent systematic chemotherapy","NOT_YET_RECRUITING","2024-03-20",{"date":36,"type":37},"2024-03-26","ACTUAL",{"date":39,"type":21},"2024-05-01",{"date":41,"type":21},"2028-05-01",{"name":43,"class":44},"Fujian Cancer Hospital","OTHER_GOV"]